Tearsheet

Regencell Bioscience (RGC)

Market Price (10/31/2025): $16.58 | Market Cap: $-
Sector: Health Care | Industry: Pharmaceuticals

Regencell Bioscience (RGC)

Market Price (10/31/2025): $16.58
Market Cap: $-
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0			Stock price has recently run up significantly 6M Rtn6 month market price return is 707%, 12M Rtn12 month market price return is 8893%
1			High stock price volatility Vol 12M is 442%

0	Stock price has recently run up significantly 6M Rtn6 month market price return is 707%, 12M Rtn12 month market price return is 8893%
1	High stock price volatility Vol 12M is 442%

Market Valuation & Key Metrics

Valuation
Key Metrics

	10/31/25	2024	2023	2022
Share Price CYE	$16.58
Market Cap CYE ($ Bil)	0.0	-	-	-
Total Debt ($ Bil)	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	0.0	0.1	0.0	0.0
Enterprise Value ($ Bil)	0.0
Valuation Ratios
P/S TTM	0.0	0.0	0.0	0.0
P/EBIT TTM	0.0	0.0	0.0	0.0
P/E TTM	0.0	0.0	0.0	0.0
Sector Ratios
P/S TTM (Sector)	3.0	3.0	2.8	2.7
P/EBIT TTM (Sector)	6.8	6.8	7.0	6.2
P/E TTM (Sector)	11.8	11.5	10.1	9.3

	10/31/25	2024	2023
Share Price CYE	$16.58
Market Cap CYE ($ Bil)	0.0	-	-
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	0.0	0.1	0.0
Enterprise Value ($ Bil)	0.0
Valuation Ratios
P/S TTM	0.0	0.0	0.0
P/EBIT TTM	0.0	0.0	0.0
P/E TTM	0.0	0.0	0.0
Sector Ratios
P/S TTM (Sector)	3.0	3.0	2.8
P/EBIT TTM (Sector)	6.8	6.8	7.0
P/E TTM (Sector)	11.8	11.5	10.1

null

RGC Stock

Return (1M):

null

Factor Drivers of Stock Movement

null

null

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
RGC Return	-	-	-12%	-62%	-53%	12477%	1797%
Peers Return	-10%	-6%	-26%	-27%	-27%	2488%	759%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	110%
Monthly Win Rates [3]
RGC Win Rate	-	60%	58%	33%	25%	67%
Peers Win Rate	22%	30%	22%	23%	32%	44%
S&P 500 Win Rate	58%	75%	42%	67%	75%	67%
Max Drawdowns [4]
RGC Max Drawdown	-	-	-35%	-67%	-69%	-28%
Peers Max Drawdown	-17%	-13%	-31%	-34%	-35%	-27%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: BGM, NSRX, RGC, RHHBY, SXTC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

Unique Key	Event	RGC	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-80.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	402.2%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	451 days	464 days

Compare to BGM, NSRX, RGC, RHHBY, SXTC

In The Past

Regencell Bioscience's stock fell -80.1% during the 2022 Inflation Shock from a high on 8/25/2021. A -80.1% loss requires a 402.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Regencell Bioscience (RGC)

Business Description

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

	Best Bets In Health Care Sector
What You Pay
P/E	�	15.3	14.1	12.3	15.4	14.0	14.0	13.6	12.8	11.8	12.4
P/EBIT	�	8.1	11.0	10.5	9.3	9.6	9.0	10.1	10.3	29.2	10.3
What You Get
Rev Chg Q	�	7.7%	40.8%	19.4%	2.8%	-4.1%	-6.6%	2.8%	10.3%	11.9%	-4.8%
Rev Chg LTM	�	3.0%	35.0%	28.5%	1.3%	5.7%	0.6%	4.8%	13.5%	9.1%	-3.3%
Rev Chg 3Y Avg	�	0.8%	35.5%	49.9%	1.0%	34.3%	0.8%	-0.9%	-12.4%	3.0%	-3.0%
FCF/Rev 3Y Avg	�	113.4%	43.4%	38.9%	29.0%	26.1%	21.6%	17.0%	13.8%	11.9%	9.0%

Trade Ideas

Select past ideas related to RGC. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	4.2%	4.2%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.3%	16.3%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.8%	3.8%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.0%	14.0%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	13.5%	13.5%	-8.0%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	4.2%	4.2%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.3%	16.3%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.8%	3.8%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.0%	14.0%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	13.5%	13.5%	-8.0%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PRAX	Praxis Precision Medicines	279.1%	161.2%
2	INBX	Inhibrx Biosciences	131.0%	409.8%
3	PUMP	ProPetro	99.6%	16.2%
4	DYN	Dyne Therapeutics	88.4%	-0.0%
5	VICR	Vicor	85.4%	89.2%
6	CELC	Celcuity	74.6%	503.2%
7	GLUE	Monte Rosa Therapeutics	73.5%	87.5%
8	NVTS	Navitas Semiconductor	72.1%	251.8%
9	LUMN	Lumen Technologies	70.3%	94.7%
10	BALY	Ballys	63.4%	4.1%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	-62.9%	5106.3%
2	LRN	Stride	-53.8%	-35.8%
3	FMC	FMC	-51.0%	-66.6%
4	FI	Fiserv	-48.3%	-68.3%
5	NFE	New Fortress Energy	-43.6%	-91.9%
6	VG	Venture Global	-41.7%
7	OGN	Organon	-40.2%	-55.0%
8	VRNS	Varonis Systems	-39.5%	-21.2%
9	ITGR	Integer	-38.5%	-52.2%
10	LENZ	LENZ Therapeutics	-37.9%	5.5%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

Peer Comparisons for Regencell Bioscience

Financials

	RGC	BGM	NSRX	RHHBY	SXTC	Median
Name	Regencel.	BGM	Nasus Ph.	Roche	China SX.
Mkt Price	16.35	9.12	7.78	40.56	1.36	9.12
Mkt Cap	-	-	-	-	-	-
Rev LTM	-	-	-	-	-	-
Op Inc LTM	-	-	-	-	-	-
FCF LTM	-	-	-	-	-	-
FCF 3Y Avg	-	-	-	-	-	-
CFO LTM	-	-	-	-	-	-
CFO 3Y Avg	-	-	-	-	-	-

Growth & Margins

	RGC	BGM	NSRX	RHHBY	SXTC	Median
Name	Regencel.	BGM	Nasus Ph.	Roche	China SX.
Rev Chg LTM	-	-	-	-	-	-
Rev Chg 3Y Avg	-	-	-	-	-	-
Rev Chg Q	-	-	-	-	-	-
QoQ Delta Rev Chg LTM	-	-	-	-	-	-
Op Mgn LTM	-	-	-	-	-	-
Op Mgn 3Y Avg	-	-	-	-	-	-
QoQ Delta Op Mgn LTM	-	-	-	-	-	-
CFO/Rev LTM	-	-	-	-	-	-
CFO/Rev 3Y Avg	-	-	-	-	-	-
FCF/Rev LTM	-	-	-	-	-	-
FCF/Rev 3Y Avg	-	-	-	-	-	-

Valuation

	RGC	BGM	NSRX	RHHBY	SXTC	Median
Name	Regencel.	BGM	Nasus Ph.	Roche	China SX.
Mkt Cap	-	-	-	-	-	-
P/S	-	-	-	-	-	-
P/EBIT	-	-	-	-	-	-
P/E	-	-	-	-	-	-
P/CFO	-	-	-	-	-	-
Total Yield	-	-	-	-	-	-
Dividend Yield	-	-	-	-	-	-
FCF Yield 3Y Avg	-	-	-	-	-	-
D/E	-	-	-	-	-	-
Net D/E	-	-	-	-	-	-

Returns

	RGC	BGM	NSRX	RHHBY	SXTC	Median
Name	Regencel.	BGM	Nasus Ph.	Roche	China SX.
1M Rtn	5.8%	-10.9%	17.0%	-3.0%	-13.4%	-3.0%
3M Rtn	23.9%	7.8%	-	4.2%	-12.8%	6.0%
6M Rtn	706.9%	-19.3%	-	2.5%	-38.7%	-8.4%
12M Rtn	8,893.4%	23.1%	-	6.2%	-70.6%	14.6%
3Y Rtn	2,156.1%	-	-	14.1%	-98.9%	14.1%
1M Excs Rtn	1.6%	-12.2%	28.0%	-11.2%	-16.7%	-11.2%
3M Excs Rtn	16.7%	-3.3%	-	-4.9%	-29.4%	-4.1%
6M Excs Rtn	685.2%	-41.0%	-	-19.3%	-60.5%	-30.1%
12M Excs Rtn	10,069.8%	-0.8%	-	-13.2%	-88.3%	-7.0%
3Y Excs Rtn	2,079.3%	-	-	-63.7%	-175.7%	-63.7%

Financials

Annual
Quarterly

$ Mil \| FY: 6/30	LTM	2024	2023	2022	2021	2020	2019
Period End	0/0/-1	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020	6/30/2019
Filing Date	0/0/-1	10/25/2024	10/27/2023	10/31/2022	10/29/2021	6/23/2021	10/29/2021
Key Financials
Total Revenue	-	0	0	0	0	0	0
EBITDA	-	-4	-6	-7	-1	-1	-0
Operating Income	-	-5	-6	-8	-1	-1	-0
Net Income	-	-4	-6	-7	-1	-1	-0
EPS	-	-0.01	-0.01	-0.02	-0.00	-0.00	-0.00
Growth Rates
Total Revenue Growth	-	-	-	-	-	-	-
EBITDA Growth	-	27.5%	21.5%	-417.6%	-68.8%	-105.3%	-
Operating Income Growth	-	24.5%	17.6%	-451.5%	-70.0%	-107.8%	-
Net Income Growth	-	26.7%	21.1%	-452.9%	-65.8%	-107.8%	-
Margins
EBITDA Margin	-	-	-	-	-	-	-
Operating Income Margin	-	-	-	-	-	-	-
Net Income Margin	-	-	-	-	-	-	-
Cash & Debt
Total Cash	�	8	12	16	0	0	0
Total Debt	0	0	0	1	4	3	2
Net Debt / (Cash)	�	-8	-11	-16	4	3	2
Cash Flows
Net Cash from Operations	-	-4	-5	-5	-1	-1	-0
Free Cash from Operations	-	-4	-5	-6	-1	-1	-0
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 6/30
Period End
Filing Date
Key Financials Quarterly
Total Revenue
Ebitda
Operating Income
Net Income
EPS
Key Financials TTM
Total Revenue TTM
Ebitda TTM
Operating Income TTM
Net Income TTM
Growth Rates Quarterly
Total Revenue Growth
EBITDA Growth
Operating Income Growth
Net Income Growth
Margins Quarterly
EBITDA Margin
Operating Income Margin
Net Income Margin
Cash & Debt
Total Cash
Total Debt
Net Debt / (Cash)
Cash Flows Quarterly
FCF from Operations
Cash Flows TTM
FCF from Operations TTM
Returns to Shareholders Quarterly
Dividends
Share Repurchases
Return on Invested Capital (ROIC) Quarterly
ROIC
Return on Invested Capital (ROIC) TTM
ROIC TTM

	1M	2M	3M	6M	1Y	3Y
Beta	-0.06	2.03	-1.54	-0.09	-0.88	-0.47
Up Beta	-7.40	0.49	1.56	0.62	0.09	-0.09
Down Beta	21.57	6.84	-6.39	-1.31	-1.47	0.48
Up Capture	-1%	184%	-75%	336%	236%	-1%
Bmk +ve Days	13	23	35	74	144	420
Stock +ve Days	10	20	27	55	110	244
Down Capture	-383%	90%	-64%	-1219%	-3498%	-2414%
Bmk -ve Days	8	19	29	52	107	330
Stock -ve Days	11	22	36	70	137	345

Short Interest

Short Interest: As Of Date	10152025
Short Interest: Shares Quantity	1,358,115
Short Interest: % Change Since 9302025	-11.5%
Average Daily Volume	281,472
Days-to-Cover Short Interest	4.83

SEC Filings

Expand for More

Report Date	Filing Date	Filing
12312024	6302025	6-K 12/31/2024
6302024	10252024	20-F 6/30/2024
12312023	6202024	6-K 12/31/2023
6302023	10272023	20-F 6/30/2023
12312022	6152023	6-K 12/31/2022
6302022	10312022	20-F 6/30/2022
12312021	6022022	6-K 12/31/2021
6302021	10292021	20-F 6/30/2021
6302020	6232021	F-1/A 6/30/2020

Insider Activity

Expand for More

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Regencell Bioscience (RGC)

Market Price (10/31/2025): $16.58 | Market Cap: $-Sector: Health Care | Industry: Pharmaceuticals

Regencell Bioscience (RGC)

Market Price (10/31/2025): $16.58Market Cap: $-Sector: Health CareIndustry: Pharmaceuticals

Market Valuation & Key Metrics

RGC Stock

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Regencell Bioscience (RGC)

Interactive Breakdown

Better Bets than Regencell Bioscience (RGC)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Regencell Bioscience

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (10/31/2025): $16.58 | Market Cap: $-
Sector: Health Care | Industry: Pharmaceuticals

Market Price (10/31/2025): $16.58
Market Cap: $-
Sector: Health Care
Industry: Pharmaceuticals